Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bamidele Ekunsanmi

Internal Medicine Rock Hill, SC Medical Doctor

NPI 1932156171 CMS profile 268627

1609 Constitution Blvd, Rock Hill, SC 29732

Open in the dashboard

General payments

$4,652

62 records reported · program years 2019–2025

Research payments

$1,770

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$80,192 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Bamidele Ekunsanmi of Rock Hill, SC is reported in the CMS Open Payments database as having received $4,652 across 62 general payments and $1,770 in research payments paid to them. Separately, studies naming them as principal investigator received $80,192 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $196 6
2024 General $3,446 25
2024 Research $1,770 3
2023 General $330 7
2022 General $44 2
2021 General $231 7
2020 General $48 3
2019 General $358 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bamidele Ekunsanmi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bamidele Ekunsanmi were reported at $196. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bamidele Ekunsanmi Internal Medicine median Middle half National median
2019 $358 $159 $48–$570 $163
2020 $48 $119 $33–$402 $114
2021 $231 $135 $37–$521 $132
2022 $44 $141 $42–$496 $149
2023 $330 $149 $45–$519 $160
2024 $3,446 $154 $47–$537 $164
2025 $196 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,617 4 payments
  2. AstraZeneca Pharmaceuticals LP $1,475 9 payments
  3. Novo Nordisk Inc $445 17 payments
  4. AbbVie, Inc. $261 7 payments
  5. Pfizer Inc. $180 9 payments
  6. ViiV Healthcare Company $125 1 payment
  7. Horizon Therapeutics plc $117 1 payment
  8. Gilead Sciences, Inc. $105 1 payment
  9. Davol Inc. $92 1 payment
  10. Exact Sciences Corporation $60 3 payments
  11. Other $174 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,330 56 payments
  2. Travel and Lodging $2,322 6 payments
Products named General payments · program years 2019–2025
  1. KRYSTEXXA Inflammation/Rare Disease $1,617 4 payments
  2. AIRSUPRA $1,475 9 payments
  3. QULIPTA $244 6 payments
  4. RYBELSUS $199 6 payments
  5. UBRELVY $194 4 payments
  6. Tresiba $146 3 payments
  7. Ozempic $128 10 payments
  8. KRYSTEXXA Krystexxa $117 1 payment
  9. Truvada $105 1 payment
  10. COLOGUARD $102 6 payments
  11. Other $634 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Lexicon Pharmaceuticals, Inc. $1,770 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 74 drugs

Part D claims

2,570

Median for Internal Medicine: 777

Drug cost

$99,898

Median for Internal Medicine: $73,373

Branded share of claims

24.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 38 $36,462
Rybelsus Semaglutide Brand 23 $23,575
Linzess Linaclotide Brand 12 $6,601
Tresiba Flextouch U-100 Insulin Degludec Brand 14 $5,554
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 18 $1,767
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 79 $1,728
Megestrol Acetate Generic 13 $1,652
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 44 $1,544
Clonidine Generic 12 $1,301
Omeprazole Generic 85 $1,252

The 10 drugs with the highest cost, of 74 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$21,299

Of which drugs: $53

Medicare patients

44

Average age 73

Services billed

751

27 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 64%
Arthritis 39%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 12 96 $32
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 17 120 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $1,617
$1,617 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $1,475
$1,475 — —
UBRELVY
  • AbbVie, Inc. $89
$89 — —
QULIPTA
  • AbbVie, Inc. $89
$89 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record